Xintela appoints Lucienne Vonk as Chief Scientific Officer
Xintela announces that Lucienne Vonk, previously Director Musculoskeletal Diseases at Xintela, has been appointed Chief Scientific Officer. She takes over the role from the CEO Evy Lundgren-Åkerlund. “Lucienne Vonk joined Xintela about 1,5 years ago and has already made a great contribution to the development of our stem cell product XSTEM. Lucienne has extensive experience […]
Targinta appoints Peter Ekolind as acting CEO
Targinta’s board has appointed Peter Ekolind as acting CEO, starting from October 1, 2022, as a part-time assignment, due to Per Norlén’s resignation as CEO. Peter Ekolind has more than 30 years of experience from operational and strategic positions at management level in the pharmaceutical and medical technology industry, from multinational companies to small development […]
Per Norlén to step down as Targinta CEO
Targinta announces that Per Norlén will leave his position as CEO of the company effective late January 2023 at the latest to take on the CEO role in another drug development company. “We have started the work of recruiting a new CEO for Targinta. In the meantime, Per will continue to support Targinta’s development activities. […]
New board of directors appointed in Targinta AB
Xintela AB announces the appointment of a new board of directors in Targinta AB, a wholly-owned subsidiary of Xintela. Jeffrey Abbey, Karin Wingstrand and Maarten de Château have been appointed as new board members. Gregory Batcheller, chairman, and Evy Lundgren-Åkerlund are already members of the board of Targinta. Gunnar Telhammar resigns as board member. The […]
Targinta recruits Per Norlén as CEO
Lund, Sweden, May 4, 2021 – Xintela announces today that Per Norlén has been recruited as CEO of Xintela’s wholly owned oncology subsidiary Targinta. He will start on 1 September 2021. Per Norlén will also have the role of Xintela’s Chief Medical Officer (CMO) from 1 July 2021. The recruitment is an important step in […]
Xintela recruits Jeffrey Abbey to Targinta
Lund, Sweden, 14 December 2020 -Xintela AB (publ) announces that Jeffrey Abbey has been recruited as a Senior Management Advisor to support further development of the wholly owned subsidiary Targinta. Mr. Abbey has more than 20 years of experience in the biopharmaceutical industry and has spent much of his career focused on the development of […]
Xintela Board recommends Maarten de Château as new Board member
Lund, Sweden, 3 December 2020 -Xintela AB (publ) announces that Maarten de Château has accepted an invitation to join the Xintela Board of Directors. The Xintela Board will recommend that shareholders formally appoint Maarten at the next shareholders meeting. In the meantime, Maarten will be adjoined to future Board meetings. Maarten de Château is currently […]
Xintela Board recommends Lars Hedbys as new Board member
Lund, Sweden, 12 November 2020 -Xintela AB (publ) announces that Lars Hedbys has accepted an invitation to join the Xintela Board of Directors. The Xintela Board will recommend that shareholders formally appoint Lars at the next shareholders meeting. In the meantime, Lars will be adjoined to future Board meetings. Lars Hedbys (born 1957) has significant […]
Xintela expands and strengthens management team
Lund, Sweden, August 19, 2020 – Xintela announces it is expanding and strengthening its management team with Peter Ekolind as COO (Chief Operating Officer) and Thomas Areschoug as CBO (Chief Business Officer). Sven Kili, who has had a combined role as COO and CMO (Chief Medical Officer), will focus on his role as CMO. “As […]
Peter Edman nominated as new board member
Lund, Sweden, 26 April 2019 – The Board of Xintela AB (publ) announces that Peter Edman has been nominated for election to the Board at the annual general meeting on the 27th of May 2019. Greg Batcheller, Karin Wingstrand and Sven Kili have been proposed for re-election. The proposal is supported by major shareholders of […]
